Dupilumab and tezepelumab in severe refractory asthma: new opportunities
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Chronic Disease"
DOI: 10.1177/20406223221097327
Abstract: Bronchial asthma is a chronic inflammatory condition with increasing prevalence worldwide that may present as heterogeneous phenotypes defined by the T2-mediated pattern of airway inflammation T2-high and T2-low asthma. Severe refractory asthma includes a subset… read more here.
Keywords: dupilumab tezepelumab; refractory; severe refractory; refractory asthma ... See more keywords